Furthermore, initial xenograft models suggest that first-generation PRMT5 inhibitors effective in MTAP-competent genetic backgrounds are cytostatic rather than cytotoxic because tumours regrew after treatment withdrawal [16]. This evidence concerns the gene PRMT5 and neoplasm.